News | January 07, 2023
Dabur India expects low to mid-single digit revenue growth for Q3 FY23
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Seeks partnership between government and private medical colleges for providing superior medical education
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Subscribe To Our Newsletter & Stay Updated
